What Ronawk does

Ronawk, Inc. is a Delaware corporation founded in 2019 and headquartered in Olathe, Kansas, that develops a proprietary biomanufacturing platform branded as Bio-OS (Biological Operating System). The platform integrates modular hardware, standardized software, and proprietary wetware (living hydrogel components called Bio-Blocks) to recreate natural cellular microenvironments, enabling continuous and reproducible mammalian cell growth. Bio-OS is configured across four application areas — Manufacturing, Assembly, Diagnostic, and Engineering — and has been validated on over 100 cell types. Per the company's terms and conditions, products are sold and licensed solely for research and development purposes, restricting use to internal R&D.

Ronawk targets biopharmaceutical and biotech companies developing cell-based therapies, regenerative medicine products, and advanced biologics, as well as academic and commercial cell producers and research institutions. The company pursues an enterprise B2B go-to-market with direct sales engagement; prospective customers initiate a "Bio-OS program" through a structured contact process on the company website, with contact forms segmented by role (Business Professional, Cell Culture Scientist, Clinician, Commercial Cell Producer, R&D Regenerative Medicine, Reseller, Student, Other). Strategic partnerships announced in 2024-2025 include Cellipont Bioservices (cGMP MSC manufacturing), The Amnion Foundation (perinatal stem cells), and collaborations with the University of Florida and Nikon for translational and analytical applications.

Ronawk has raised approximately $8.4 million across disclosed funding rounds between 2020 and 2023, including seed and exempt securities offerings, with investors including Accelerate Venture Partners and undisclosed backers. Leadership comprises co-founders Dr. A.J. Mellott (CEO, tissue engineer) and Heather Decker (CTO, chemist/microscopist), alongside President & COO Tom Jantsch and CBDO Scott Leigh. The company operates with 11-50 employees and has reported no revenue. U.S. regulators are reportedly exploring Bio-OS as a new biomanufacturing standard, which, if formalized, could entrench the platform in regulated manufacturing workflows.

Name

Ronawk

Legal name

Ronawk, Inc.

Website

https://ronawk.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Ronawk develops the Bio-OS platform, integrating modular hardware, software, and proprietary hydrogel wetware to enable scalable, reproducible mammalian cell manufacturing for biotech companies, research institutions, and commercial cell producers.

Ownership category

akta.pro rank

Product category

Bioprocess Technology

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Equipment and Supplies Manufacturing (3391)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers) (HLAGAIAG)

akta.pro secondary industries

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD), Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware) (IMAAAAAG), In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

Keywords

• Biologics manufacturing platform
• Cell culture technology
• Bioprocess hardware software
• Hydrogel cell growth
• Regenerative medicine tools

Headquarters

HQ city

Olathe

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Bio-OS Platform Products: Ronawk sells biological products (Bio-Blocks/hydrogels and potentially associated hardware/software) for research and development purposes. The Terms and Conditions indicate products are sold and licensed solely for research and development purposes, with payment terms of 30 days net. The company appears to operate on a direct B2B transactional model with no explicit recurring or subscription components described.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Ronawk develops and sells the Bio-OS™ platform, a Biological Operating System that integrates modular hardware, standardized software, and proprietary hydrogel wetware (Bio-Blocks®) to recreate natural cellular microenvironments, enabling continuous, scalable, and reproducible mammalian cell production for research and development use. The platform is offered in four configurations—Manufacturing, Assembly, Diagnostic, and Engineering—and is sold and licensed under 30-day net terms solely for R&D applications to biotech, pharmaceutical, research, and commercial cell producers.

Product overview

Ronawk offers a unified platform architecture centered on Bio-OS™. Bio-OS™ is the primary platform combining modular hardware, standardized software, and living wetware to make cell behavior consistent, predictable, and scalable. The Bio-Blocks® product, the company's first innovation of modular hydrogels, evolved into this Bio-OS platform. Bio-OS is configured for four application areas: Manufacturing (continuous cell production), Assembly (controlled assembly of multiple cell types into tissues), Diagnostic (extracting multiple data points from a single sample), and Engineering (control over cell phenotype).

Differentiator

Problem solved

Functional benefit

Brands

• Bio-OS: Ronawk's biological operating system platform that provides hardware, software, and wetware integration to make living systems programmable, scalable, and investable. It serves as biology's throughput architecture and programmability layer.

Products and services

• Bio-OS™ Platform Ronawk's flagship Biological Operating System that combines modular hardware, standardized software, and living wetware (Bio-Blocks hydrogels) to recreate natural cellular microenvironments. Provides standardized, repeatable compute cores of biology that make mammalian cell behavior consistent, predictable, and scalable. Sold and licensed for research and development use only via direct enterprise sales engagement.
• Bio-Blocks® Modular hydrogel product that recreates real tissue environments, enabling mammalian cells to grow continuously while preserving function. Marketed as a registered product trademark and sold for research and development purposes as the wetware foundation that evolved into the Bio-OS platform.

Quantifiable outcome

• ~90% of drug candidates fail in development
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and supporting.

• Cellipont BioservicescoreStrategic or Co-development Partner · 19 November 2025Strategic collaboration to advance scalable expansion of high-quality mesenchymal stem cells (MSCs) for advanced biologics and regenerative medicine applications. Combines Cellipont's cGMP manufacturing and process development expertise with Ronawk's Bio-OS platform. Aims to close the manufacturing gap that has limited broad clinical adoption of MSC-based therapies, potentially accelerating therapeutic development across the biotech landscape.
• The Amnion Foundation, InccoreStrategic or Co-development Partner · 4 November 2025Partnership to advance perinatal stem cell research. Collaborates with Ronawk to leverage Bio-OS platform capabilities for perinatal stem cell applications, expanding the platform's reach into specialized cell therapy research areas.
• Micro-GRX and University of FloridasupportingStrategic or Co-development Partner · 1 September 2024Collaboration on translational research in advanced tissue engineering aboard the International Space Station, validating Bio-OS technology in microgravity environments for advanced tissue engineering applications.
• NikonsupportingTechnology or Integration · 1 September 2024Nikon published an application note on resolving subcellular detail in tissue mimetic culture using Ronawk's Bio-OS technology, demonstrating technical integration and validation of the platform.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Emulate Inc. Developer of organ-on-chip platforms for biological research. Comparable in aiming to replace traditional cell culture with physiologically relevant microfluidic systems.

Broad incumbents

• Thermo Fisher Scientific (Cell Therapy): Provides cell culture media, instruments, and bioproduction services. Broad incumbent with overlapping capabilities in cell manufacturing and process development.
• Corning Life Sciences: Major supplier of cell culture vessels, surfaces, and bioprocess systems. Incumbent in the very cell culture market Ronawk is positioning Bio-OS to disrupt.
• Sartorius AG: Global bioprocess equipment leader (bioreactors, cell expansion platforms). Direct incumbent in biomanufacturing infrastructure that Ronawk aims to redefine for mammalian cells.
• Lonza Group: Leading CDMO for cell and gene therapies. Comparable in serving the same biotech customers Ronawk targets, with broader capabilities and much larger scale.

Direct peers

• Aspect Biosystems: Biotechnology company developing 3D bioprinted tissue therapeutics. Direct peer in modular tissue engineering and biofabrication platforms.
• Organovo: Pioneer in 3D bioprinting of human tissues, including hydrogels. Direct peer in tissue engineering using hydrogel-based biofabrication.
• Cellink (BICO): Leading bioprinting company offering hardware, bioinks, and workflows. Direct peer in tissue biofabrication and modular cell culture systems.
• Miltenyi Biotec: Provides cell manufacturing platforms, including the Prodigy system for automated cell processing. Direct peer in cell-based therapy bioprocessing.
• Cellipont Bioservices: CDMO specializing in cell-based therapy manufacturing. Ronawk's strategic partner for MSC expansion and a direct peer in the scalable cell manufacturing space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ronawk-inc
• Xx.com/ronawkllc
• Facebookfacebook.com/ronawkinc

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ronawk